Fractyl Health

Fractyl is a biotechnology firm dedicated to addressing metabolic disorders such as obesity and type 2 diabetes. This is accomplished through the development of novel therapies that target the underlying causes of these conditions, as opposed to merely treating their symptoms. Their primary emphasis is on the gastrointestinal tract and pancreas, with the objective of developing therapeutic interventions that rectify the fundamental pathology. Revita, a heat-based technique designed to enhance blood sugar regulation in diabetics, and Rejuva, an early-stage gene therapy platform, are both in their current pipeline. By doing so, they hope to revolutionize the treatment of metabolic diseases from chronic management to possible remedies, thereby saving lives and preventing the spread of these pervasive conditions. Check here for more information on how to align sales and revenue.